Major publications in the critical care pharmacotherapy literature: 2019

Melanie Smith Condeni1, Alyson T Basting2, Patrick G Costello3

  • 1Medical University of South Carolina, 150 Ashley Avenue, Charleston, SC 29425, USA.

Journal of Critical Care
|January 10, 2021
PubMed

Insights

This review summarizes 2019 critical care pharmacotherapy research, including guidelines and trials on sepsis, cardiac arrest, and delirium management. Key findings impact clinical practice for critically ill patients.

Area of Science:

  • Critical care medicine
  • Pharmacotherapy
  • Evidence-based medicine

Background:

  • The Critical Care Pharmacotherapy Literature Update (CCPLU) Group systematically reviews relevant literature.
  • High-impact articles are identified using Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria.

Purpose of the Study:

  • To summarize influential meta-analyses and trials in critical care pharmacotherapy from 2019.
  • To provide expert perspectives on the clinical practice impact of these publications.

Main Methods:

  • Monthly screening of 36 journals for impactful articles.
  • Review of 113 articles published in 2019 based on GRADE criteria.
  • Focus on articles with a GRADE 1A rating, including clinical practice guidelines, meta-analyses, and original research trials.

Main Results:

  • Summaries of clinical practice guidelines on polymyxins and antiarrhythmic drugs for cardiac arrest.
  • Meta-analyses on antipsychotic use in delirium, stress ulcer prophylaxis (SUP), and vasoactive medications in septic shock and cardiac arrest.
  • Evaluation of original research trials concerning delirium, sedation, neuromuscular blockade, SUP, anticoagulation reversal, and hemostasis.

Conclusions:

  • This review offers a summary and expert opinion on key 2019 critical care pharmacotherapy publications.
  • The findings highlight the clinical practice impact of influential research in the field.
Abstract

Related Concept Videos

Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
252
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
562
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
672
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
938
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
97
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
100